-
Item confirms peer-reviewed
GLP-1 drugs cut weight by 6.7 kg in antipsychotic-treated patients in eight small trials
A meta-analysis of eight randomised trials in 664 patients taking antipsychotics found GLP-1 receptor agonists reduced body weight by 6.74 kg, BMI by 2.37 kg/m² and HbA1c by 0.61 percentage points, with semaglutide the largest effect and more gastrointestinal adverse events.
-
Item new peer-reviewed
Second primary lung cancers in Sweden have risen steadily since 1980
A Swedish national registry analysis covering 1961 to 2021 identified 853 second primary lung cancers, rising almost linearly from 1980, with a relative risk of 3.59 compared with first lung cancer and up to 20-fold after early-onset female adenocarcinoma.
-
Item confirms peer-reviewed
Lung screening invitations in Scotland drew a 24% response, lowest in deprived areas
Inviting people with a recorded smoking history from Scottish primary care records to a lung health check produced a 23.8% response across four health boards, lower in more deprived practices, and non-responders were more often current smokers (69.3% vs 49.8%).
-
Item confirms peer-reviewed
Québec's first universal nirsevimab season cut infant RSV hospitalisations by two-thirds
A province-wide evaluation of Québec's first universal nirsevimab campaign found RSV-associated hospitalisations in infants aged 0-5 months fell 66% (95% CI 58-71) in 2024-25, with acute bronchiolitis emergency visits down 35%.
-
Item refines peer-reviewed
GLP-1 drugs did not lower new sleep apnoea diagnoses in UK diabetes records
In UK primary-care records covering 206,000 adults with type 2 diabetes and obesity, starting a GLP-1 receptor agonist rather than a weight-neutral DPP-4 inhibitor was not associated with fewer new diagnoses of obstructive sleep apnoea (HR 1.07, 95% CI 0.93-1.23).
-
Item new peer-reviewed
An oral KRAS G12D inhibitor shrank tumours in a third of treated pancreatic cancers
In a phase 1 trial of 74 heavily pretreated patients with KRAS G12D-mutant advanced solid tumours, the oral inhibitor GFH375 produced confirmed responses in 35.1% of pancreatic cancers and 35.7% of non-small cell lung cancers, with median overall survival of 9.9 and 13.4 months respectively.
-
Item new peer-reviewed
Most dementia trial participants had mixed brain pathology, not the one targeted
Among 67 autopsied participants in Alzheimer's and related dementia trials at a Kentucky research centre, only 10–29% had solely the pathology the intervention was designed to target, with a mean of 2.54 pathological features per person.
-
Item new peer-reviewed
Wildfire PM2.5 exposure is linked to shorter survival in older US lung cancer patients
A SEER-Medicare cohort of 414,016 patients aged 65 or older with lung cancer linked residential zip-code estimates of wildfire-related and non-wildfire PM2.5 from 2008 to 2019 to all-cause mortality, separating the two sources of fine particulate exposure.
-
Item new peer-reviewed
An exosome biomarker with CA19-9 detected early-stage pancreatic cancer in 1,785 people
A prospective study of 1,785 individuals in four countries reports that the PANXEON exosome-based blood biomarker, combined with carbohydrate antigen 19-9, detects early-stage pancreatic ductal adenocarcinoma with high sensitivity.
-
Item new preprint
LLM-extracted autopsy brain features classify neurodegenerative disease with 75% accuracy
A fine-tuned large language model scored 39 features from narrative gross descriptions in 5,613 Mayo Clinic brain autopsies, and classification reached 0.75 accuracy, from 0.93 sensitivity for progressive supranuclear palsy to 0.03 for mixed Alzheimer–Lewy body disease.
-
Item new preprint
A local multi-agent AI system deidentified multimodal hospital data at 99.8% sensitivity
A locally deployable multi-agent system combining multimodal large language models, task-specific networks and rule-based steps removed 99.82% of injected identifiers across text, imaging, handwriting and audio while preserving 99.61% of clinically important content.
-
Item confirms preprint
Known dementia risk factors explain only a little of exceptional cognitive ageing
In 3,513 Whitehall II participants aged 65 and over, education, female sex, absence of hypertension, fewer depressive symptoms, higher fruit and vegetable intake and greater social activity were each modestly associated with 'SuperAger' cognitive status, none strongly.
